Neovacs to Present Clinical Development Update On IFNα Kinoid in Dermatomyositis

PARIS and BOSTON, May 04, 2017 (GLOBE NEWSWIRE) — Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Thérèse Croughs, M.D., Chief Medical Officer of Neovacs, will present an update on the clinical development of the Company’s IFNα Kinoid in dermatomyositis at the 2nd World Conference on Myositis, to be held May 5-8, 2017, in Potomac, Maryland, USA.